AMINOSYN-PF 7% SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

HISTIDINE; L-PROLINE; SERINE; TAURINE; L-TYROSINE; GLYCINE; L-ISOLEUCINE; L-LEUCINE; L-LYSINE (L-LYSINE ACETATE); METHIONINE; L-PHENYLALANINE; L-THREONINE; TRYPTOPHAN; L-VALINE; L-ALANINE; L-ARGININE; L-ASPARTIC ACID; GLUTAMIC ACID

Tilgjengelig fra:

HOSPIRA HEALTHCARE ULC

ATC-kode:

B05BA01

INN (International Name):

AMINO ACIDS

Dosering :

220MG; 570MG; 347MG; 50MG; 44MG; 270MG; 534MG; 831MG; 475MG; 125MG; 300MG; 360MG; 125MG; 452MG; 490MG; 861MG; 370MG; 576MG

Legemiddelform:

SOLUTION

Sammensetning:

HISTIDINE 220MG; L-PROLINE 570MG; SERINE 347MG; TAURINE 50MG; L-TYROSINE 44MG; GLYCINE 270MG; L-ISOLEUCINE 534MG; L-LEUCINE 831MG; L-LYSINE (L-LYSINE ACETATE) 475MG; METHIONINE 125MG; L-PHENYLALANINE 300MG; L-THREONINE 360MG; TRYPTOPHAN 125MG; L-VALINE 452MG; L-ALANINE 490MG; L-ARGININE 861MG; L-ASPARTIC ACID 370MG; GLUTAMIC ACID 576MG

Administreringsrute:

INTRAVENOUS

Enheter i pakken:

250ML/500ML

Resept typen:

Ethical

Terapeutisk område:

CALORIC AGENTS

Produkt oppsummering:

Active ingredient group (AIG) number: 1850892001; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2016-07-29

Preparatomtale

PRESCRIBING INFORMATION
AMINOSYN7-PF 7%
AMINOSYN7-PF 10%
(amino acids for injection 7% and 10% - pediatric formula)
SULFITE-FREE
NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION
Hospira Healthcare Corporation
DATE OF PREPARATION:
1111 Dr. Frederik-Philips
OCTOBER 26, 2009
St-Laurent, Quebec
H4M 2X6
CONTROL #131561
_PRESCRIBING INFORMATION; Aminosyn®-PF 7% & 10% _
_Page 2 of 12 _
PRESCRIBING INFORMATION
AMINOSYN
7
-PF 7%
AMINOSYN
7
-PF 10%
(amino acids for injection 7% and 10% - pediatric formula)
Sulfite-Free
THERAPEUTIC OR PHARMACOLOGIC CLASSIFICATION
Nutritive Supplement for Intravenous Infusion
ACTIONS AND CLINICAL PHARMACOLOGY
Total parenteral nutrition consists of appropriate amino acids,
electrolytes, trace metals, vitamins and an
energy source; this may be accomplished in children by administering
AMINOSYN
7
-PF 7% and 10% (amino
acids for injection 7% and 10% - pediatric formula), Sulfite-Free plus
electrolytes, concentrated dextrose or
fat emulsion, vitamins and trace metals.
Clinical studies in infants who required TPN therapy showed that
infusion of AMINOSYN
7
-PF resulted in
plasma amino acid concentrations approximating those of normal breast
or formula fed infants. In addition,
weight gains, nitrogen balance, and serum protein concentrations were
consistent with an improving
nutritional status.
AMINOSYN
7
-PF contains a mixture of essential and nonessential amino acids as
well as taurine. The amino
acid composition has been specifically formulated to provide a
well-tolerated nitrogen source for nutritional
support and therapy for infants and young children. When administered
in conjunction with a cysteine
hydrochloride additive, AMINOSYN
7
-PF results in plasma amino acid concentrations approximating a
profile consistent with that of a breastfed infant.
AMINOSYN
7
-PF 7% and 10% provide amino acids to promote protein synthesis and
wound healing, and to
reduce the rate of endogenous protein catabolism.
AMINOSYN
7
-PF can be given by central venous infusion in combination with
concentrated dextrose,
cys